Updated November 12, 2025
Pfizer’s stock is modestly higher in Wednesday trading. Around 2:00 p.m. ET, PFE changed hands near $25.94, up about 1.7% on the day. Earlier prints showed an intraday range of $25.25–$25.95 versus Tuesday’s close at $25.51.
What’s moving Pfizer today
Pfizer schedules CFO appearance at Jefferies London Healthcare Conference (webcast).
This morning the company invited investors to a live webcast with CFO Dave Denton on Wednesday, November 19, 2025 (9:00 a.m. GMT)—a near‑term catalyst where guidance framing, cost discipline, and integration priorities typically get airtime. A replay will be posted within 24 hours.
Media/market chatter turns constructive.
A mid‑day column highlighted CNBC’s Jim Cramer calling Pfizer’s valuation “unfathomable,” with discussion centered on the dividend yield, pipeline, and post‑COVID reset. It’s sentiment, not a rating, but it added a tailwind to today’s narrative. Insider Monkey
Context you need: the Metsera obesity deal
Investors are still digesting Pfizer’s up to $10 billion agreement to acquire Metsera, a clinical‑stage obesity‑drug developer. Metsera’s board favored Pfizer’s increased offer—$65.60 in cash plus a CVR of up to $20.65—over Novo Nordisk’s, citing lower antitrust risk. A shareholder vote is slated for November 13. The deal would re‑establish Pfizer in the GLP‑1 weight‑management race after earlier internal setbacks.
Analysts view the transaction as a high‑stakes swing into a market expected to expand sharply over the next decade. Breakingviews also noted the competitive dynamics and regulatory backdrop that helped tip the contest in Pfizer’s favor.
Earnings, guidance and dividend—today’s reference points
- Guidance: On Nov. 4, Pfizer raised and narrowed its 2025 adjusted EPS outlook to $3.00–$3.15, following a Q3 beat. That reset is still the financial anchor heading into the Jefferies conversation next week.
- Dividend: Pfizer declared a $0.43 Q4 cash dividend (record Nov. 7, payable Dec. 1). The company’s investor site shows the ex‑dividend/record date and payout detail. On trailing metrics, yield sits in the mid‑6% range.
Regulatory climate watch
On the regulatory front, a STAT deep‑dive today examines internal dynamics at the FDA’s vaccine leadership, a reminder that policy signals can sway expectations around COVID‑era revenues and future immunization products (where Pfizer remains a major player). It’s not a Pfizer‑specific ruling, but it’s part of the backdrop investors are tracking.
Today’s takeaway for PFE
- Price action: Modest green as traders position around next week’s CFO remarks; intraday range has been tight, suggesting a “wait‑for‑updates” tone. Bloomberg+1
- Near‑term catalyst path: Jefferies webcast (Nov. 19) → Metsera shareholder vote (Nov. 13) → continuing integration clarity and pipeline milestones.
- Storyline: A richer, high‑yield value case buttressed by a cleaner 2025 guide and a bold obesity bet that could reshape medium‑term growth if the pipeline delivers.
Key facts at a glance
- Price (approx. 2:00 p.m. ET): $25.94, +1.7% day‑over‑day.
- Day range: $25.25–$25.95; Prior close: $25.51.
- 2025 EPS guidance: $3.00–$3.15 (raised/narrowed Nov. 4).
- Dividend: $0.43 (record Nov. 7; payable Dec. 1).
- Metsera deal: Up to $10B; $65.60 cash + up to $20.65 CVR; vote Nov. 13.
What to watch next
- Management tone at Jefferies: Listen for confirmation on cost controls, deleveraging pace, and how Metsera programs would slot into 2026–2028 growth.
- Obesity pipeline clarity: Regulatory, manufacturing, and clinical timelines for Metsera assets once the deal closes.
- Dividend narrative: With a payout tracked closely by income investors, any commentary on capital allocation will matter.
This article summarizes developments dated November 12, 2025, and intraday market data referenced with time stamps. Always check an official quote source before making trading decisions.
